Tracing the Genealogy of Psilocybin
Close your eyes and imagine an Earth before humans, before borders, before time itself. Before Doordash and doomscroll, before innocence and guilt, there was only this: the Precambrian soup from which all organic life emerged. Cells dividing and asteroids colliding, hulking trees and sprawling vines growing and decaying beneath orange-purple skies. Sheets of salt and granite cleaving against one another as hideous oceans of molten lava obliterate everything in their path. Epochs rising and falling in a single breath. The howling of wind and the screeching of apes.
Somehow, by some stroke of extraordinary grace, out of this primordial chaos emerged a molecule called psilocybin, the active compound in psilocybe cubensis. The likelihood of such an emergence happening spontaneously is akin to a tornado ripping through a junkyard and accidentally assembling a Rolls Royce.
Nature doesn’t make mistakes. Every cell has a story; every cell is the end point of a wildly complex saga, a culmination of billions of years of selective evolution arriving at an assemblage of proteins and amino acids that forms the building block of all organic life. Nature abides by the rule of energy conservation at all cost, never wasting precious resources on something that doesn’t serve a distinct evolutionary purpose. What exactly psilocybin’s purpose is has been a matter of fierce debate since its discovery, but up until recently, one thing was agreed upon: psilocybin evolved through a single, predictable route, and its genealogy could be traced back to the emergence of mushrooms in the genus Psilocybe.
A groundbreaking new study published in Angewandte Chemie International Edition has shattered that consensus.
Inocybe vs. Psilocybe: Two Distinct Biosynthetic Pathways
Researchers from Friedrich Schiller University Jena in Germany have discovered that nature, that divine architect, didn’t just invent psilocybin once. It invented it twice, through two completely distinct and unrelated biosynthetic pathways. In a stunning display of what biologists call “convergent evolution”, a completely different group of mushrooms–the Inocybe genus, or “fiber caps”–developed its own unique biological machinery to produce the exact same psychedelic molecule as mushrooms in the genus Psilocybe. A suitable metaphor might be that of two painters working in separate corners of the Earth, using completely different tools and having had no communication whatsoever with one another, somehow producing the exact same painting. It’s nothing short of a miracle.
Buried beneath layers of dense jargon and complex graphs is a discovery that challenges our understanding of fungal evolution, rewrites the biochemistry of psychedelics, and opens up a brand-new frontier for biotechnology. If sentences like the following: “…we characterized four recombinantly produced biosynthesis enzymes of this species in vitro: IpsD, a pyridoxal-5′-phosphate-dependent l-tryptophan decarboxylase, the kinase IpsK, and two near-identical methyltransferases, IpsM1 and IpsM2…” make your head spin, we’ve got you covered. We’re going to break down the key findings of this article and explain why, exactly, they constitute such a breakthrough in magic mushroom biology.
Standard Mechanisms of Psilocybin Synthesis
To understand how radical this discovery really is, we must first look at what we thought we knew. For years, the gold standard for psilocybin biosynthesis was the pathway taken by mushrooms in the genus Psilocybe. This pathway is a linear, predictable 4-step process by which the common amino acid L-tryptophan is converted into psilocybin. It goes like this:
- The process begins with L-tryptophan, a standard amino acid found in most living organisms
- The first enzyme, PsiD, removes a carboxyl group, turning the L-tryptophan into the much trippier Tryptamine. This process is called “decarboxylation”, and it’s a critical step in moving the molecule away from general protein building and toward the psychoactive pathway
- Next, the enzyme PsiH adds an oxygen and a hydrogen atom (a hydroxyl group) to the 4 position on the molecule, creating 4-hydroxy-tryptamine
- The kinase enzyme PsiK then adds a phosphate group, stabilizing the molecule and preparing it for the final stage in its journey. This creates Norbaeocystin, a compound with its own set of psychoactive properties and an essential component of the mushroom’s overall “entourage effect”
- Finally, a methyltransferase enzyme called PsiM adds two methyl groups to the nitrogen tail of the molecule. This final touch converts Norbaeocystin into Psilocybin, and the magic is complete
Up until the discoveries outlined in this article were made, this was assumed to be the only way that psilocybin was biosynthesized in mushrooms: Decarboxylation → Hydroxylation → Phosphorylation → Methylation, with the enzymes PsiD, PsiH, PsiK, and PsiM doing all of the heavy lifting along the way. This error was downstream from another critical misconception–namely, the assumption that mushrooms in the genus Psilocybe were the only fungi that made magic.
Genetic Architecture of the Inocybe “Fiber Cap”
Psilocybin has been detected in over 200 species of basidiomycete fungi. Among these are the Inocybe mushrooms, often called “fiber caps.” Inocybe is a massive, diverse genus of mushrooms, only distantly related to Psilocybe. Many are toxic, containing muscarine, but a few, like Inocybe corydalina (the green-flush fibre cap), contain psilocybin. 
Scientists assumed that the presence of psilocybin in Inocybe corydalina was the result of a process called “horizontal gene transfer”. In the fungal world and across nature, it’s not uncommon for species to “swap” genetic tools for producing pest-repelling, human-attracting compounds that ensure the survival of themselves and their comrades. The prevailing consensus was that millions of years ago, an ancestor of the fibre cap mushroom swapped genetic material with an ancestor of the magic mushroom, copying the Psi. recipe for itself.
But when researchers at Friedrich Schiller University sequenced the genome of Inocybe corydalina, they stumbled across something utterly baffling: the standard Psi. genes weren’t there. No PsiD, no PsiK, and no PsiM. And yet the mushrooms were undeniably producing psilocybin. This consensus-defying paradox launched the investigation that led to the identification of a completely novel biosynthetic pathway, with resounding implications for biotechnology, pharmaceutical research, and therapeutic applications across the mycological world.
The Case for the Convergent Evolution of Psilocybin
Earlier in this piece, we brushed over a phenomenon called “convergent evolution”. Briefly, this can be explained as the emergence of the same exact trait or gene expression among otherwise distinct organisms. Consider the fact that both birds and bats have wings. Birds and bats are not closely related; one is a dinosaur descendant, and the other is an avian mammal. However, they both faced the same evolutionary problem (how to move through the air) and came up with the same physical solution (wings), even though the bone structures and mechanics of those wings are different.
Similarly to the birds and the bats, both Inocybe and Psilocybe appear to have faced overlapping evolutionary pressures from their environments. What exactly those pressures were is a matter of speculation that ranges from everyday pest-deterrence to the divine intervention of benevolent aliens from faraway planets. In response to these mysterious outside forces, both of these species “decided” to manufacture psilocybin, but because they didn’t share the same genetic toolkit, they went about it using completely different tools.
The researchers confirmed that the enzymes in Inocybe are chemically and structurally distinct from those in Psilocybe. They share almost no DNA sequence similarities. Nature, that wild and wondrous entrepreneur, built two different factories to produce the exact same product.
The Ips Cluster: Biotech Potential and Future Outlook
In the absence of the expected Psi. genes, researchers identified a new cluster of genes that mushrooms in the genus Inocybe use to produce psilocybin, which they termed the “Ips cluster”. The “Ips” pathway is a fascinating mirror image of the standard pathway. It uses different chemical reactions and, crucially, performs them in an entirely different order. As detailed above, mushrooms in the genus Psilocybe begin the process with Decarboxylation, and then move on to Hydroxylation. In fiber cap mushrooms, this process is reversed–the Hydroxylation happens first, before the molecule is decarboxylated. This is more similar to how mammals (including humans) produce serotonin. It suggests that Inocybe mushrooms are using a biosynthetic logic that is closer to mammalian biology than to their fungal cousins in the Psilocybe genus.
This study is more than just a niche academic curiosity for mycologists. It’s a goldmine of sorts for biotechnologists and people invested in the future of psychedelic medicine. We are currently in the midst of a psychedelic renaissance, with magic mushrooms being fast-tracked by the FDA as a breakthrough therapy for severe depression, PTSD, and addiction. As demand for clinical-grade psilocybin grows, we need efficient ways to manufacture it. Currently, we can extract it from mushrooms (inconsistent), synthesize it chemically (expensive and uses harsh solvents), or use biosynthesis (using yeast or bacteria engineered with mushroom genes). Until now, bio-engineers only had one set of tools: the Psi enzymes from Psilocybe. If those enzymes were finicky or slow in a lab setting, there were no alternatives. The discovery of the Ips cluster provides a second toolkit.
These findings are recent, and a great deal of questions remain. What, exactly, the biotechnical and medical relevance of this new gene cluster will be remains a mystery–likewise, what new discoveries will be made about the history of this miracle molecule called psilocybin. Once again, we are reminded that nature is the most innovative chemist on Earth. Faced with environmental pressures and a need to survive, two completely unrelated mushrooms stumbled upon the exact same chemical solution, following two completely unrelated formulas. For us at ITW, the beneficiaries of this evolutionary redundancy, the implications are profound. We have gained a deeper understanding of fungal genetics, a potential explanation for the varied effects of different mushroom species, and a powerful new set of biological keys to unlock the future of psychedelic medicine. As we continue to explore the fungal kingdom, one is left to wonder: if nature invented psilocybin twice, what other “magic” recipes are hiding on the forest floor, waiting to be discovered?